Advertisement

Collaboration › Details
Valneva–Leucadia: investor conference, 202111 supply service Valneva presents at Jefferies 2021 London Healthcare Conference
![]() |
Period | 2021-11-16 � 2021-11-17 |
![]() |
Region | London, Greater London |
Country | United Kingdom (GB) | |
![]() |
Partner, 1st | Valneva S.E. (Nasdaq: VALN, Euronext Paris: VLA) |
Group | Valneva (Group) | |
![]() |
Product | Jefferies 2021 London Healthcare Conference London + DIGITAL |
Product 2 | VLA15 lyme disease vaccine | |
![]() |
Person | Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring) |
Person 2 | Lawrence, David (Valneva 201708– CFO before Acambis + Chiron Vaccines + GSK) | |
Valneva S.E.. (11/8/21). "Press Release: Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference". Saint-Herblain.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies London Healthcare Conference on November 16 and 17, 2021.
Valneva’s Chief Executive Officer Thomas Lingelbach and acting Chief Financial Officer David Lawrence will notably discuss the Company’s late stage vaccine candidates against Lyme disease (VLA15), chikungunya (VLA1553) and COVID-19 (VLA2001).
Valneva recently reported positive Phase 3 results for VLA2001[1], currently the only whole virus, inactivated, adjuvanted vaccine candidate against COVID-19 in clinical trials in Europe. The Company also announced last week the closing of a $102.0 million Global Offering[2].
Valneva’s presentation will take place on November 16, 2021 at 4:20pm GMT and can be accessed via the following link: https://wsw.com/webcast/jeff201/vla.pa/2050524. To request a meeting at the event, please contact your representative at Jefferies.
About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.
Valneva Investor and Media Contacts
Laetitia Bachelot-Fontaine
VP, Global Communications and European Investor Relations
M +33 (0)6 4516 7099
[email protected]
Joshua Drumm, Ph.D.
VP, Global Investor Relations
M +001 917 815 4520
[email protected]
[1] Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
[2] Valneva Announces Closing of Approximately $102.0 Million Global Offering
Record changed: 2024-12-20 |
Advertisement

More documents for Valneva (Group)
- [1] Valneva S.E.. (8/1/24). "Press Release: Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate". Saint-Herblain & Schlieren....
- [2] Valneva S.E.. (7/22/24). "Press Release: CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine". Oslo & Saint-Herblain....
- [3] Valneva S.E.. (7/1/24). "Press Release: Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, Ixchiq". Saint Herblain....
- [4] Valneva S.E.. (11/10/23). "Press Release: Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, Ixchiq". Saint Herblain....
- [5] Valneva S.E.. (11/9/23). "Press Release: Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates". Saint Herblain....
- [6] Valneva S.E.. (11/7/23). "Press Release: Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference". Saint Herblain....
- [7] Valneva S.E.. (10/25/23). "Press Release: Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment". Saint Herblain....
- [8] Valneva S.E.. (9/25/23). "Press Release: Valneva Announces New Ixiaro Supply Contract with the U.S. Government Worth a Minimum of $32 Million". Saint Herblain....
- [9] NorthX Biologics. (7/3/23). "Press Release: NorthX Biologics, a Leading Nordic Development and Manufacturing Organisation Announces Acquisition of a Biologics Manufacturing Unit from Valneva". Matfors....
- [10] Valneva S.E.. (11/17/22). "Press Release: Valneva Appoints Dipal Patel as Chief Commercial Officer". Saint-Herblain....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top